Flupentixol + Melitracen
Presentation: Adelax® Tablets: Pink, round, biconvex, film-coated tablet. Each tablet
contains Flupentixol 0.5 mg as Dihydrochloride BP and Melitracen 10 mg as Hydrochloride
Description: Adelax® is a combination preparation of two well known and time tested
molecules: flupentixol - a neuroleptic with anxiolytic and antidepressant properties of its
own when given in small doses, and melitracen - a bipolar thymoleptic with activating
properties in low doses. In combination, the compounds exert antidepressant, anxiolytic and
Maximum serum concentration is reached in about 4 hours after oral administration of both
flupentixol and melitracen. The biological half-life of flupentixol is about 35 hours and that
of melitracen is about 19 hours. The combination of flupentixol and melitracen does not
seem to influence the pharmacokinetic properties of the individual compounds.
Indications: Adelax® is indicated for the treatment of different types of anxiety, depression
and apathy. These include:
Psychosomatic affections accompanied by anxiety and apathy
Dysphoria and depression in alcoholics and drug addicts
Adelax® is also indicated for maintenance in psychogenic depressions and other psychoses.
Dosage & administration: Adults: Usually 2 tablets daily: morning and noon. In severe
cases the morning dose may be increased to 2 tablets. Elderly patients: 1 tablet in the
morning. Maintenance dose: Usually 1 tablet in the morning. In case of insomnia and severe
restlessness additional treatment with sedative in the acute phase is recommended.
Side-effects: In the recommended doses side-effects are rare. Restlessness, insomnia,
hypomania reported, rarely dizziness, tremor, visual disturbances, headache,
hyperprolactinaemia, extrapyramidal symptoms may be observed.
Contra-indications: The immediate recovery phase after myocardial infarction. Defects in
bundle-branch conduction. Untreated narrow angle glaucoma. Acute alcohol, barbiturate
and opiate intoxications. Flupentixol-melitracen combination should not be given to patients
who have received a MAO-inhibitor within two weeks. Not recommended for excitable or
overactive patients since its activating effect may lead to exaggeration of these
Precautions: If previously the patient has been treated with tranquilizers with sedative
effect these should be withdrawn gradually.
Use in pregnancy and lactation: Flupentixol-melitracen combination should preferably not be
given during pregnancy and lactation. Drug interactions: Flupentixol-melitracen combination
may enhance the response to alcohol, barbiturates and other CNS depressants.
Simultaneous administration of MAO-inhibitors may cause hypertensive crises. Neuroleptics
and thymoleptics reduce the antihypertensive effect of guanethidine and similar acting
compounds and thymoleptics enhance the effects of adrenaline and noradrenaline.
Overdosage: Symptoms: Incase of overdosage the symptoms of intoxications by
melitracen, especially of anticholinergic nature, dominate. More rarely extrapyramidal
symptoms due to flupentixol occur. Treatment: Symptomatic and supportive. Gastric lavage
should be carried out as soon as possible and activated charcoal may be administered.
Measures aimed at supporting the respiratory and cardiovascular systems should be
instituted. Epinephrine (adrenaline) must not be used for such patients. Convulsions may be
treated with diazepam and extrapyramidal symptoms with biperiden.
Store in a cool dry place. Protect from light
Adelax® Tablets: Cartons of 80 tablets in Alu-Alu blister
Promoted by: alifpharma.com
Brand: ACI Limited.